BIOMAT Database Logo BIOMAT Database Logo

Large-scale preparation of human thrombin: polyethylene glycol potentiates the factor Xa-mediated activation of prothrombin. 1998

H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Okubo, Japan. QYN00365@niftyserve.or.jp

We investigated the ability of polyethylene glycol 4000 to accelerate thrombin generation in a mixture of prothrombin and factor X at concentrations of 1-30%. In the presence of 5 mM of CaCl2, polyethylene glycol 4000 promoted prothrombin activation at concentrations above 1%. The peak of activation was seen at levels of 14 and 20% of polyethylene glycol 4000. The effect of the polyethylene glycol was remarkably dependent on its molecular weight; molecular weights greater than 2000 were required for accelerating thrombin generation. Under optimal conditions, polyethylene glycol 4000, in the presence of CaCl2, promoted conversion of all of the prothrombin into thrombin and its derivatives. We conclude that polyethylene glycol 4000, at concentrations ranging from 14 to 20%, effectively accelerates thrombin generation in the presence of 5 mM of CaCl2. This new method for preparing thrombin is based on the use of polyethylene glycol 4000 and CaCl2 and is applicable to the manufacture of thrombin.

UI MeSH Term Description Entries
D008420 Manufactured Materials Substances and materials manufactured for use in various technologies and industries and for domestic use. Manufactured Material,Material, Manufactured,Materials, Manufactured
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D002122 Calcium Chloride A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning. Calcium Chloride Dihydrate,Calcium Chloride, Anhydrous
D004345 Drug Industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function. Industries, Pharmaceutic,Industry, Drug,Industry, Pharmaceutic,Industry, Pharmaceutical,Pharmaceutical Industry,Drug Industries,Industries, Drug,Industries, Pharmaceutical,Pharmaceutic Industries,Pharmaceutic Industry,Pharmaceutical Industries
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
Activation of duck prothrombin by factor Xa and thrombin.
January 1985, Acta biochimica Polonica,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
The conversion of prothrombin to thrombin. III. The factor Xa-catalyzed activation of prothrombin.
December 1974, The Journal of biological chemistry,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
Activation of human factor V by factor Xa and thrombin.
February 1990, Biochemistry,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
The conversion of prothrombin to thrombin. V. The activation of prothrombin by factor Xa in the presence of phospholipid.
December 1974, The Journal of biological chemistry,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
[Kinetics of prothrombin activation by factor Xa].
January 1981, Ukrainskii biokhimicheskii zhurnal (1978),
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
Large-scale preparation of thrombin from human plasma.
January 2008, Thrombosis research,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
Inhibition by human thrombomodulin of factor Xa-mediated cleavage of prothrombin.
July 1986, The Journal of clinical investigation,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
The activation of prothrombin by platelet-bound factor Xa.
March 1980, European journal of biochemistry,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
Large-scale preparation and preliminary characterization of human thrombin.
January 1971, Biochimica et biophysica acta,
H Kaetsu, and J Mizuguchi, and T Hamamoto, and K Kamimura, and Y Yoshida, and T Nakagaki, and Y Ogata, and S Miyamoto, and A Funatsu
The conversion of prothrombin to thrombin. II. Differentiation between thrombin- and factor Xa-catalyzed proteolyses.
January 1974, The Journal of biological chemistry,
Copied contents to your clipboard!